Data from An EGFR-Induced <i>Drosophila</i> Lung Tumor Model Identifies Alternative Combination Treatments

Abstract

&lt;div&gt;Abstract&lt;p&gt;Lung cancer is the leading cause of cancer-associated mortality. Mutations in the &lt;i&gt;EGFR&lt;/i&gt; gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resistances. We expressed constitutively active EGFR (EGFR&lt;sup&gt;CA&lt;/sup&gt;) exclusively in the airway system of &lt;i&gt;Drosophila melanogaster&lt;/i&gt; and performed comprehensive phenotyping. Ectopic expression of EGFR&lt;sup&gt;CA&lt;/sup&gt; induced massive hyper- and metaplasia, leading to early death. We used the lethal phenotype as a readout and screened a library of FDA-approved compounds and found that among the 1,000 compounds, only the tyrosine kinase inhibitors (TKI) afatinib, gefitinib, and ibrutinib rescued lethality in a whole-animal screening approach. Furthermore, we screened the library in the presence of a subtherapeutic afatinib dose and identified bazedoxifene as a synergistically acting compound that rescues EGFR-induced lethality. Our findings highlight the potential of &lt;i&gt;Drosophila&lt;/i&gt;-based whole-animal screening approaches not only to identify specific EGFR inhibitors but also to discover compounds that act synergistically with known TKIs. Moreover, we showed that targeting the EGFR together with STAT-signaling is a promising strategy for lung tumor treatment.&lt;/p&gt;&lt;/div&gt;